BRCA2 and breast cancer: Lack of prospective data on the level of risk reduction from RRM for non-BRCA carriers at increased BC risk leads us to use estimates from BRCA1/BRCA2 PV carriers.31 To address uncertainty, we conducted sensitivity analyses for a wide range of this parameter (62% to 98%).